SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-3.6%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$614M
AUM Growth
-$3.99M
(-0.65%)
Cap. Flow
+$47.9M
Cap. Flow
% of AUM
7.81%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
127
New
28
Increased
30
Reduced
32
Closed
11
Top Buys
| 1 |
Skye Bioscience
SKYE
|
$10.4M |
| 2 |
ASML
ASML
|
$10.1M |
| 3 |
Apple
AAPL
|
$9.27M |
| 4 |
Amazon
AMZN
|
$9.08M |
| 5 |
Salesforce
CRM
|
$8.64M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$17.9M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$9.57M |
| 3 |
Camtek
CAMT
|
$9.14M |
| 4 |
Nova
NVMI
|
$6.23M |
| 5 |
SentinelOne
S
|
$5.62M |
Sector Composition
| 1 | Healthcare | 71.02% |
| 2 | Technology | 20.47% |
| 3 | Communication Services | 3.65% |
| 4 | Consumer Discretionary | 3.59% |
| 5 | Utilities | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Immatics
IMTX
$662M
| $8.5M | 1.16% |
731,111
+65,000
| +10% | +$755K |
|
27
Perspective Therapeutics
CATX
$251M
| $7.85M | 1.07% |
786,909
-457,453
| -37% | -$4.56M |
|
28
Pharvaris
PHVS
$1.41B
| $7.58M | 1.03% |
403,265
+10,388
| +3% | +$195K |
|
29
Merck
MRK
$210B
| $7.38M | 1.01% |
59,600
-44,000
| -42% | -$5.45M |
|
30
Rezolute
RZLT
$630M
| $7.34M | 1% |
1,707,999
+711,289
| +71% | +$3.06M |
|
|
CYBN
31
Cybin
CYBN
$142M
| $6.93M | 0.95% |
673,195
| – | – |
|
|
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
| $6.77M | 0.92% |
1,692,166
-38,248
| -2% | -$153K |
|
33
Ionis Pharmaceuticals
IONS
$9.64B
| $6.68M | 0.91% |
+140,238
| New | +$6.68M |
|
|
INZY
34
DELISTED
Inozyme Pharma
INZY
| $6.52M | 0.89% |
1,462,724
+89,817
| +7% | +$401K |
|
35
AbbVie
ABBV
$374B
| $6.52M | 0.89% |
38,000
| – | – |
|
36
Palo Alto Networks
PANW
$128B
| $6.1M | 0.83% |
+36,000
| New | +$6.1M |
|
|
37
SentinelOne
S
$6.01B
| $5.97M | 0.81% |
283,804
-267,014
| -48% | -$5.62M |
|
38
Tower Semiconductor
TSEM
$6.96B
| $5.88M | 0.8% |
149,600
-30,000
| -17% | -$1.18M |
|
39
Applied Materials
AMAT
$124B
| $5.81M | 0.79% |
24,604
-7,396
| -23% | -$1.75M |
|
40
Enphase Energy
ENPH
$4.85B
| $5.66M | 0.77% |
56,792
+9,609
| +20% | +$958K |
|
41
Novartis
NVS
$248B
| $5.32M | 0.73% |
50,000
| – | – |
|
42
Acadia Pharmaceuticals
ACAD
$4.34B
| $5.32M | 0.73% |
327,539
+202,539
| +162% | +$3.29M |
|
43
Mineralys Therapeutics
MLYS
$1.94B
| $5.18M | 0.71% |
442,752
-216,051
| -33% | -$2.53M |
|
44
4D Molecular Therapeutics
FDMT
$302M
| $5.09M | 0.69% |
242,526
+80,365
| +50% | +$1.69M |
|
45
Micron Technology
MU
$133B
| $4.87M | 0.66% |
+37,000
| New | +$4.87M |
|
46
Day One Biopharmaceuticals
DAWN
$766M
| $4.79M | 0.65% |
347,627
-145,000
| -29% | -$2M |
|
47
Catalyst Pharmaceutical
CPRX
$2.42B
| $4.46M | 0.61% |
288,000
| – | – |
|
48
Rocket Pharmaceuticals
RCKT
$358M
| $4.46M | 0.61% |
206,933
+23,211
| +13% | +$500K |
|
49
JFrog
FROG
$5.58B
| $4.43M | 0.6% |
117,881
-106,500
| -47% | -$4M |
|
50
89bio
ETNB
$1.37B
| $4.22M | 0.58% |
526,547
+10,665
| +2% | +$85.4K |
|